To the Editor: Chronic medication-induced immunosuppression is a known risk factor for keratinocyte cancer (KC). [1] [2] [3] To determine which immunosuppressants are most significantly associated with increased KC, we retrospectively analyzed 3398 subjects with a biopsy finding of squamous cell cancer (SCC) or basal cell cancer (BCC) by using 8002 pathology reports at Stanford Hospital and Clinics between 2005 and 2015. We excluded reports of residual or recurrent skin cancers (Supplementary Materials and Methods; available at http://www.jaad.org).
We subdivided our cohort into 3 groups on the basis of the number of KCs developed over 10 years: (1) 1 KC, (2) 2 to 5 KCs, and (3) more than 6 KCs. In the cohort, 60.1% developed 1 KC, 31.8% developed 2 to 5 KCs, and 8.1% developed 6 or more KCs. A comparable distribution was observed for BCC and SCC frequency. Overall, patients with 6 or more BCCs or SCCs represented the top 5% of the respective cohorts.
A total of 572 out of 3398 subjects with KCs had 6 months or more use of immunosuppressant medications, including azathioprine (n ¼ 39), mycophenolate mofetil (n ¼ 158), cyclosporine (n ¼ 103), sirolimus (n ¼ 50), and tacrolimus (n ¼ 169) (Table I) . Twenty-five percent of the subjects who developed 6 or more SCCs had a history of solid organ transplant compared with 7.7% of subjects who developed 6 or more BCCs, highlighting the strong role of transplant status in SCC risk. Higher proportions of subjects with 6 or more KCs had taken immunosuppressant medication(s) compared to subjects in the groups with 1 or 2 to 5 KCs, particularly azathioprine and sirolimus. When adjusted for age, sex, race, and transplant status, however, only azathioprine use was significantly associated with development of 6 or more KCs-an odds ratio of 3.91 compared with 1 KC (95% confidence interval [CI], 1.65-9.23; P ¼ .002) (Table II) . To determine whether azathioprine use is preferentially associated with BCC or SCC development, we performed a subanalysis of azathioprine use in subjects with a high frequency of BCC and SCC. Subjects with 6 or more BCCs were 4.92 times more likely to have used azathioprine (95% CI, 1.23-19.67; P ¼ .024) than those with 1 BCC. A similar association was observed for 6 or more SCCs-an odds ratio of 4.78 compared with 1 SCC (95% CI, 1.63-14.07; P ¼ .005). Patients with 6 or more KCs were more likely to have taken azathioprine longer and as part of a solid transplant immunosuppression regimen. Azathioprine was associated with increased risk for high-frequency KC development, defined as 6 or more KCs in a 10-year period. The association of azathioprine with KC development suggests a preferential risk with azathioprine as compared with that with other immunosuppressants, possibly because of a photosensitizing effect 4 and increased accumulation of 6-thioguanine in DNA. 5 Although other immunosuppressants may also contribute to increased risk for development of KC, this increase did not reach significance in our cohort, potentially because of sample size, limitation as a singleinstitution study, and inability to compare cumulative doses. 5 The results support the need for broader studies investigating the association and mechanism by which azathioprine contributes to KC development. 
SUPPLEMENTARY MATERIALS AND METHODS

Study population
We performed a retrospective cohort study of all basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) on which a biopsy was performed between 2005 and 2015 at Stanford Hospital and Clinics. Approval for this study was obtained with a waiver of consent from the Stanford Institutional Review Board (institutional review board protocol 36263). Clinical pathology reports on the BCC and SCC biopsy specimens were obtained from electronic medical records and parsed to obtain information on number, date, histologic subtype, patient age, patient sex, patient ethnicity, and anatomic location. Computer scripts were used to parse the case reports involving BCC and SCC via a
